Spironolactone improves cardiac sympathetic nerve activity and symptoms in patients with congestive heart failure

Journal of Nuclear Medicine

Volumn 43, Issue 10, 2002, Pages 1279-1285

  Kasama, Shu ^a   Toyama, Takuji ^a   Kumakura, Hisao ^a   Takayama, Yoshiaki ^a   Ichikawa, Shuichi ^a   Suzuki, Tadashi ^a   Kurabayashi, Masahiko ^a  

^a GUNMA UNIVERSITY   (Japan)

Author keywords

Aldosterone; Heart failure; Radionuclide imaging

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; ALDOSTERONE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOOP DIURETIC AGENT; SPIRONOLACTONE; THALLIUM 201;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG EFFECT; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART SCINTISCANNING; HUMAN; MALE; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYMPATHETIC TONE; SYMPTOMATOLOGY;

3-IODOBENZYLGUANIDINE; AGED; ALDOSTERONE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DIGOXIN; DIURETICS; DRUG THERAPY, COMBINATION; FEMALE; HEART; HEART FAILURE, CONGESTIVE; HUMANS; IODINE RADIOISOTOPES; MALE; RADIOPHARMACEUTICALS; SPIRONOLACTONE; STROKE VOLUME; SYMPATHETIC NERVOUS SYSTEM;

EID: 0036787678     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-717.
2. Dzau VJ, Colucci WS, Hollenberg NK, Williams GH. Relation of the reninangiotensin-aldosterone system to clinical state in congestive heart failure. Circulation. 1981;63:645-651.
3. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation. 1990;82:1730-1736.
4. Weber KT, Villarreal D. Aldosterone and antialdosterone therapy in congestive heart failure. Am J Cardiol. 1993;71:3A-11A.
5. Barr CS, Lang CC, Hanson J, Amott M, Kennedy N, Struthers AD. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol. 1995;76:1259-1265.
6. MacFadyen RJ, Barr CS, Struthers AD. Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res. 1997;35:30-34.
7. Wang W. Chronic administration of aldosterone depresses baroreceptor reflex function in the dog. Hypertension. 1994;24:571-575.
8. Duprez DA, De Buyzere ML, Rietzschel ER, et al. Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients. Eur Heart J. 1998;19:1371-1376.
9. Rocha R, Chander PN, Khanna K, Zuckerman A, Stier CT Jr. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension. 1998;31:451-458.
10. Henderson EB, Kahn JK, Corbett JR, et al. Abnormal 1-123 metaiodobenzylguanidine myocardial washout and distribution may reflect myocardial adrenergic derangement in patients with congestive cardiomyopathy. Circulation. 1988;78:1192-1199.
11. Yamakado K, Takeda K, Kitano T, et al. Serial change of iodine-123 metaiodobenzylguanidine (MIBG) myocardial concentration in patients with dilated cardiomyopathy. Eur J Nucl Med. 1992;19:265-270.
12. 123I]metaiodobenzylguanidine scintigraphy. Circulation. 1994;89:2843-2451.
13. Merlet P, Valette H, Dubois-Rande JL, et al. Iodine 123-labeled metaiodobenzylguanidine imaging in heart disease. J Nucl Cardiol. 1994;1:S79-S85.
14. Schofer J, Spielmann R, Schuchert A. Weber K, Schluter M. Iodine-123 meta-iodobenzylguanidine scintigraphy: a noninvasive method to demonstrate myocardial adrenergic nervous system disintegrity in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 1988;12:1252-1258.
15. Glowniak JV, Turner FE, Gray LL. Palac RT, Lagunas-Solar MC, Woodward WR. Iodine-123 metaiodobenzylguanidine imaging of the heart in idiopathic congestive cardiomyopathy and cardiac transplants. J Nucl Med. 1989;30:1182-1191.
16. Merlet P, Valette H, Dubois-Rande JL, et al. Prognostic value of cardiac meta-iodobenzylguanidine imaging in patients with heart failure. J Nucl Med. 1992;33:471-477.
17. Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr. 1989;2:358-367.
18. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation. 1991;83:1849-1865.
19. Brilla CG, Pick R, Tan LB, Janicki JS. Weber KT. Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res. 1990;67:1355-1364.
20. Struthers AD. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure. J Card Fail. 1996;2:47-54.
21. Klug D, Robert V, Swynghedauw B. Role of mechanical and hormonal factors in cardiac remodeling and the biologic limits of myocardial adaptation. Am J Cardiol. 1993;71:46A-54A.
22. Brilla CG, Matsubara LS, Weber KT. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol. 1993;25:563-575.
23. Barr CS, Naas A, Freeman M, Lang CC, Struthers AD. QT dispersion and sudden unexpected death in chronic heart failure. Lancet. 1994;343:327-329.
24. Fukuoka S, Hayashida K, Hirose Y, et al. Use of iodine-123 metaiodobenzylguanidine myocardial imaging to predict the effectiveness of beta-blocker therapy in patients with dilated cardiomyopathy. Eur J Nucl Med. 1997;24:523-529.
25. Kakuchi H, Sasaki T, lshida Ishida Y, Komamura K. Miyatake K. Clinical usefulness of 1231 meta-iodobenzylguanidine imaging in predicting the effectiveness of beta blockers for patients with idiopathic dilated cardiomyopathy before and soon after treatment. Heart. 1999;81:148-152.
26. Suwa M, Otake Y, Moriguchi A, et al. Iodine-123 metaiodobenzylguanidine myocardial scintigraphy for prediction of response to beta-blocker therapy in patients with dilated cardiomyopathy. Am Heart J. 1997;133:353-358.
27. 123I-MIBG myocardial imaging in patients with dilated cardiomyopathy after beta-blocker or angiotensin-converting enzyme inhibitor therapy. J Nucl Med. 1999;40:217-223.
28. Alderman J, Grossman W. Are beta-adrenergic-blocking drugs useful in the treatment of dilated cardiomyopathy? Circulation. 1985;71:854-857.
29. Packer M. Pathophysiological mechanisms underlying the effects of beta-adrenergic agonists and antagonists on functional capacity and survival in chronic heart failure. Circulation. 1990;82(2 suppl):177-188.
30. Sato H, Hori M, Ozaki H, et al. Exercise-induced upward shift of diastolic left ventricular pressure-volume relation in patients with dilated cardiomyopathy: effects of beta-adrenoceptor blockade. Circulation. 1993;88:2215-2223.
31. Tsutamoto T, Wada A, Maeda K, et al. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol. 2001;37:1228-1233.
32. Parthenakis FI, Prassopoulos VK, Koukouraki SI, et al. Segmental pattern of myocardial sympathetic denervation in idiopathic dilated cardiomyopathy: relationship to regional wall motion and myocardial perfusion abnormalities. J Nucl Cardiol. 2002;9:15-22.
33. Sisson JC, Wieland DM, Sherman P, Mangner TJ, Tobes MC, Jacques S Jr. Metaiodobenzylguanidine as an index of the adrenergic nervous system integrity and function. J Nucl Med. 1987;28:1620-1624.
34. Tobes MC, Jaques S Jr, Wieland DM, Sisson JC. Effect of uptake-one inhibitors on the uptake of norepinephrine and metaiodobenzylguanidine. J Nucl Med. 1985;26:897-907.
35. Gasnier B. Roisin MP, Scherman D, Coornaert S, Desplanches G, Henry JP. Uptake of meta-iodobenzylguanidine by bovine chromaffin granule membranes. Mol Pharmacol. 1986;29:275-280.
36. Kline RC, Swanson DP, Wieland DM, et al. Myocardial imaging in man with 1-123 meta-iodobenzylguanidine. J Nucl Med. 1981;22:129-132.
37. Nakajo M. Shimabukuro K, Yoshimura H, et al. Iodine-131 metaiodobenzylguanidine intra- and extravesicular accumulation in the rat heart. J Nucl Med. 1986;27:84-89.
38. 123I-MIBG scintigraphy for predicting prognosis in patients with dilated cardiomyopathy. Nucl Med Commun. 1999;20:529-535.
39. Nishimura T, Morozumi T, Hod M. 1-123 MIBG scintigraphy for the estimation of the beta-blocker therapy in patients with dilated cardiomyopathy: a multicenter trial [abstract]. J Nucl Med. 1996;37(suppl):183P.